| 1. |
- Bengtsson, Kenneth, et al.
(författare)
-
Så kan Sverige bli ledande nation i resurseffektivitet
- 2016
-
Ingår i: Dagens Nyheter. - 1101-2447. ; :2016-04-30
-
Tidskriftsartikel (populärvet., debatt m.m.)abstract
- Ny rapport. Det svenska näringslivet kan bli mer hållbart, resurssmart och därmed internationellt konkurrenskraftigt. Men för det behövs en tydlig politisk avsiktsförklaring och riktlinjer. Vi har listat sex områden där policyutveckling brådskar, skriver företrädare för näringsliv, forskning och myndigheter i en gemensam uppmaning.
|
|
| 2. |
|
|
| 3. |
- Runnemalm, Henrik, et al.
(författare)
-
Accuracy in thermal analysis of laser
- 1995
-
Ingår i: Computational methods and experimental measurements VII. - Southampton : WIT Press. - 1853123137 ; , s. 85-92
-
Konferensbidrag (refereegranskat)abstract
- The paper focuses on the problem of obtaining accurate thermal fields despite the uncertainty of the thermal heat input and thermal properties at high temperatures. The net heat input is the primary factor for obtaining an accurate temperature field. A good correlation between simulations and experiments is obtained. The net heat input during laser welding a bead on a thin plate made of austenitic stainless steel is determined using a water calorimeter. Transient temperature is measured by thermocouples. The FEM is used in the numerical simulation of the process
|
|
| 4. |
- Stockfelt, Marit, et al.
(författare)
-
Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial
- 2021
-
Ingår i: Arthritis Research & Therapy. - : Springer Science and Business Media LLC. - 1478-6354 .- 1478-6362. ; 23:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background The type I interferon (IFN) gene signature is present in a subgroup of patients with early rheumatoid arthritis (RA). Protein levels of IFN alpha have not been measured in RA and it is unknown whether they associate with clinical characteristics or treatment effect. Methods Patients with early untreated RA (n = 347) were randomized to methotrexate combined with prednisone, certolizumab-pegol, abatacept, or tocilizumab. Plasma IFN alpha protein levels were determined by single molecular array (Simoa) before and 24 weeks after treatment initiation and were related to demographic and clinical factors including clinical disease activity index, disease activity score in 28 joints, swollen and tender joint counts, and patient global assessment. Results IFN alpha protein positivity was found in 26% of the patients, and of these, 92% were double-positive for rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA). IFN alpha protein levels were reduced 24 weeks after treatment initiation, and the absolute change was similar irrespective of treatment. IFN alpha protein positivity was associated neither with disease activity nor with achievement of CDAI remission 24 weeks after randomization. Conclusion IFN alpha protein positivity is present in a subgroup of patients with early RA and associates with double-positivity for autoantibodies but not with disease activity. Pre-treatment IFN alpha positivity did not predict remission in any of the treatment arms, suggesting that the IFN alpha system is distinct from the pathways of TNF, IL-6, and T-cell activation in early RA. A spin-off study of the NORD-STAR randomized clinical trial, NCT01491815 (ClinicalTrials), registered 12/08/2011, .
|
|
